LeMaitre Vascular (NASDAQ:LMAT) Upgraded to “Buy” by BidaskClub

Share on StockTwits

LeMaitre Vascular (NASDAQ:LMAT) was upgraded by research analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued on Friday, BidAskClub reports.

LMAT has been the topic of several other research reports. Barrington Research set a $64.00 price objective on SurModics and gave the company a “buy” rating in a research note on Thursday, May 2nd. Zacks Investment Research lowered GENEL ENERGY PL/ADR from a “buy” rating to a “hold” rating in a research note on Tuesday, May 7th. Finally, ValuEngine lowered W&T Offshore from a “hold” rating to a “sell” rating in a research note on Friday, April 26th. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $31.00.

LMAT traded down $0.48 on Friday, hitting $30.42. 65,933 shares of the company were exchanged, compared to its average volume of 125,349. LeMaitre Vascular has a 12 month low of $21.79 and a 12 month high of $38.99. The company has a market cap of $598.39 million, a P/E ratio of 36.21, a PEG ratio of 3.02 and a beta of 1.14. The company has a fifty day moving average price of $27.50.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Wednesday, May 1st. The medical instruments supplier reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.02). LeMaitre Vascular had a return on equity of 16.76% and a net margin of 20.92%. The company had revenue of $28.48 million for the quarter, compared to the consensus estimate of $27.94 million. During the same quarter in the previous year, the company posted $0.19 EPS. The business’s revenue was up 9.6% on a year-over-year basis. As a group, sell-side analysts predict that LeMaitre Vascular will post 0.83 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in LMAT. BNP Paribas Arbitrage SA grew its holdings in shares of LeMaitre Vascular by 66,640.0% during the first quarter. BNP Paribas Arbitrage SA now owns 3,337 shares of the medical instruments supplier’s stock valued at $103,000 after buying an additional 3,332 shares during the last quarter. Municipal Employees Retirement System of Michigan purchased a new position in LeMaitre Vascular during the fourth quarter valued at $106,000. Metropolitan Life Insurance Co. NY grew its stake in LeMaitre Vascular by 373.8% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 5,629 shares of the medical instruments supplier’s stock valued at $133,000 after acquiring an additional 4,441 shares in the last quarter. BB&T Corp purchased a new position in LeMaitre Vascular during the first quarter valued at $203,000. Finally, Globeflex Capital L P grew its stake in LeMaitre Vascular by 26.5% during the first quarter. Globeflex Capital L P now owns 6,578 shares of the medical instruments supplier’s stock valued at $204,000 after acquiring an additional 1,378 shares in the last quarter. Hedge funds and other institutional investors own 77.16% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Recommended Story: Price Target

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.